Equillium Inc to participate in BTIG's Virtual Biotechnology Conference Transcript
Hi, this is Bert Hazlett with the 3:30 session on our second day of BTIG's first virtual biotechnology conference. It is not our first biotechnology conference. It is our first virtual one, and I hope it's the last virtual one, quite frankly. It's been flimsy days, and we're actually finishing in a very, very strong manner. I'm thrilled that [something] is able to take the time today to participate.
We have Equillium with us today, and representing from them is going to be Dr. Krishna Polu, Chief Medical Officer, as well as Jason Keyes, the Chief Financial Officer as well. So thank you.
Equillium is a company focused on a -- your product, EQ001 or itolizumab, a first-in-class clinically validated antibody that targets the immune checkpoint receptor, the CD6, which is a co-stimulatory receptor that plays a role in modulating the activation, proliferation, differentiation, and trafficking of effector T cells.
Equillium is focused on the development of the molecule in multiple different indications: severe immuno-inflammatory disorder,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
